The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
Saved in:
| Title: | The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression. |
|---|---|
| Authors: | Xiao L; Children's Cancer Institute, Lowy Cancer Research Institute, University of New South Wales, Randwick, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Randwick, NSW, Australia., Karsa M; Children's Cancer Institute, Lowy Cancer Research Institute, University of New South Wales, Randwick, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Randwick, NSW, Australia., Ronca E; Children's Cancer Institute, Lowy Cancer Research Institute, University of New South Wales, Randwick, NSW, Australia., Bongers A; Children's Cancer Institute, Lowy Cancer Research Institute, University of New South Wales, Randwick, NSW, Australia., Kosciolek A; Children's Cancer Institute, Lowy Cancer Research Institute, University of New South Wales, Randwick, NSW, Australia., El-Ayoubi A; Children's Cancer Institute, Lowy Cancer Research Institute, University of New South Wales, Randwick, NSW, Australia., Revalde JL; Children's Cancer Institute, Lowy Cancer Research Institute, University of New South Wales, Randwick, NSW, Australia.; Australian Cancer Research Foundation (ACRF) Drug Discovery Centre for Childhood Cancer, Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia., Seneviratne JA; Children's Cancer Institute, Lowy Cancer Research Institute, University of New South Wales, Randwick, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Randwick, NSW, Australia., Cheung BB; Children's Cancer Institute, Lowy Cancer Research Institute, University of New South Wales, Randwick, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Randwick, NSW, Australia., Cheung LC; Leukaemia Translational Research Laboratory, Telethon Kids Cancer Centre, Telethon Kids Institute, Perth, WA, Australia.; Curtin Medical School, Curtin University, Perth, WA, Australia.; Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia., Kotecha RS; Leukaemia Translational Research Laboratory, Telethon Kids Cancer Centre, Telethon Kids Institute, Perth, WA, Australia.; Curtin Medical School, Curtin University, Perth, WA, Australia.; Department of Clinical Haematology, Oncology, Blood and Marrow Transplantation, Perth Children's Hospital, Perth, WA, Australia.; Division of Paediatrics, School of Medicine, University of Western Australia, Perth, WA, Australia., Newbold A; Gene Regulation Laboratory, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia., Bjelosevic S; Gene Regulation Laboratory, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia., Arndt GM; Children's Cancer Institute, Lowy Cancer Research Institute, University of New South Wales, Randwick, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Randwick, NSW, Australia.; Australian Cancer Research Foundation (ACRF) Drug Discovery Centre for Childhood Cancer, Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia., Lock RB; Children's Cancer Institute, Lowy Cancer Research Institute, University of New South Wales, Randwick, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Randwick, NSW, Australia., Johnstone RW; Gene Regulation Laboratory, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia., Gudkov AV; Department of Cell Stress Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, United States., Gurova KV; Department of Cell Stress Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, United States., Haber M; Children's Cancer Institute, Lowy Cancer Research Institute, University of New South Wales, Randwick, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Randwick, NSW, Australia., Norris MD; Children's Cancer Institute, Lowy Cancer Research Institute, University of New South Wales, Randwick, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Randwick, NSW, Australia.; University of New South Wales Centre for Childhood Cancer Research, Sydney, NSW, Australia., Henderson MJ; Children's Cancer Institute, Lowy Cancer Research Institute, University of New South Wales, Randwick, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Randwick, NSW, Australia., Somers K; Children's Cancer Institute, Lowy Cancer Research Institute, University of New South Wales, Randwick, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Randwick, NSW, Australia. |
| Source: | Frontiers in oncology [Front Oncol] 2022 May 23; Vol. 12, pp. 863329. Date of Electronic Publication: 2022 May 23 (Print Publication: 2022). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2022.863329 |
